Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS)

被引:0
|
作者
A. Cantù Rajnoldi
S. Fenu
G. Kerndrup
E. R. van Wering
C. M. Niemeyer
I. Baumann
机构
[1] Istituti Clinici di Perfezionamento,Dip.to di Medicina di Laboratorio
[2] Azienda Ospedaliera San Giovanni-Addolorata UOD Ematologica,Institute of Pathology
[3] Odense University Hospital,Division of Hematology and Oncology, Department of Pediatrics and Adolescent Medicine
[4] Dutch Childhood Leukemia Study Group,Institute of Pathology
[5] University Hospital Freiburg,undefined
[6] University Erlangen-Nuremberg,undefined
来源
Annals of Hematology | 2005年 / 84卷
关键词
Myelodysplastic syndrome; Morphological features of dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
In the absence of genetic abnormalities, the diagnoses of myelodysplastic syndromes (MDS) is primarily based on the presence of dysplasia in blood and marrow cells. Currently, there is no standardized approach to evaluate dysplasia. International cooperative study groups like the European Working Group on MDS in Childhood (EWOG-MDS) depend, however, on a concordance in diagnoses by their national reference centres for morphology. In EWOG-MDS, the morphological diagnoses of all cases enrolled from Scandinavia, the Netherlands, Germany, the Czech Republic, Austria and Italy are established by five experienced pathologists or hematologists cooperating in a morphology board. To study their concordance in evaluating myelodysplastic disorders, members of the morphology board initiated blinded reviews of smears of blood and bone marrow aspirates of known cases. Four features of dysplasia in granulopoiesis, erythropoiesis and megakaryopoiesis were assessed on May–Grünwald–Giemsa stained smears. In a final review of six blinded cases, good concordance for these features was achieved among the five observers. Accurately defined and restrictively applied cellular features of dysplasia are an important tool to improve and ensure the concordance in the diagnosis of MDS among investigators. For cooperative groups, agreement on the evaluation of the morphological assessment of dysplasia is a prerequisite.
引用
收藏
页码:429 / 433
页数:4
相关论文
共 50 条
  • [31] Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group
    Latagliata, Roberto
    Niscola, Pasquale
    Fianchi, Luana
    Faglioni, Laura
    Campagna, Alessia
    Maurillo, Luca
    Sarlo, Chiara
    Piccioni, Annalina
    Criscuolo, Marianna
    Carmosino, Ida
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Villiva, Nicoletta
    De Benedictis, Daniela
    Battistini, Roberta
    Fenu, Susanna
    Breccia, Massimo
    Mancini, Stefano
    Voso, Maria Teresa
    Spiriti, Maria Antonietta Aloe
    Buccisano, Francesco
    BLOOD, 2017, 130
  • [32] Myelodysplastic syndrome (MDS) after acute promyelocytic leukemia (APL): The European APL Group experience.
    Lobe, J
    Rigal-Huguet, F
    Vekhoff, A
    Desablens, B
    Bordessoule, D
    Mounier, C
    Ferrant, A
    Sanz, M
    Fey, M
    Chomienne, C
    Degos, L
    Fenaux, P
    BLOOD, 2002, 100 (11) : 334A - 334A
  • [33] Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
    A Porwit
    A A van de Loosdrecht
    P Bettelheim
    L Eidenschink Brodersen
    K Burbury
    E Cremers
    M G Della Porta
    R Ireland
    U Johansson
    S Matarraz
    K Ogata
    A Orfao
    F Preijers
    K Psarra
    D Subirá
    P Valent
    V H J van der Velden
    D Wells
    T M Westers
    W Kern
    M C Béné
    Leukemia, 2014, 28 : 1793 - 1798
  • [34] Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
    Alba Rubio-San-Simón
    Natasha K. A. van Eijkelenburg
    Raoull Hoogendijk
    Henrik Hasle
    Charlotte M. Niemeyer
    Michael N. Dworzak
    Marco Zecca
    Marta Lopez-Yurda
    Julie M. Janssen
    Alwin D. R. Huitema
    Marry M. van den Heuvel-Eibrink
    Eric J. Laille
    Harm van Tinteren
    Christian M. Zwaan
    Pediatric Drugs, 2023, 25 : 719 - 728
  • [35] Hematopoietic stem cell transplantation after a myeloablative conditioning regimen in children with refractory cytopenia:: results of a retrospective analysis from the EWOG-MDS group
    Locatelli, F.
    Noellke, P.
    Fischer, A.
    Bader, P.
    Bernardo, M. E.
    Bergstrasser, E.
    Hasle, H.
    van den Heuvel, M.
    Kabisch, H.
    Korthof, E.
    Stary, J.
    Strahm, B.
    Trebo, M.
    Zecca, M.
    Zintl, F.
    Niemeyer, C.
    LEUKEMIA RESEARCH, 2007, 31 : S39 - S39
  • [36] Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
    Rubio-San-Simon, Alba
    van Eijkelenburg, Natasha K. A.
    Hoogendijk, Raoull
    Hasle, Henrik
    Niemeyer, Charlotte M.
    Dworzak, Michael N.
    Zecca, Marco
    Lopez-Yurda, Marta
    Janssen, Julie M.
    Huitema, Alwin D. R.
    van den Heuvel-eibrink, Marry M.
    Laille, Eric J.
    van Tinteren, Harm
    Zwaan, Christian M.
    PEDIATRIC DRUGS, 2023, 25 (06) : 719 - 728
  • [37] Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies
    Strahm, Brigitte
    Amann, Roland
    De Moerloose, Barbara
    Dworzak, Michael
    Hasle, Henrik
    Schmugge, Markus
    Stary, Jan
    van den Heuvel-Eibrink, Marry M.
    Zecca, Marco
    Schlegelberger, Brigitte
    Locatelli, Franco
    Niemeyer, Charlotte M.
    BLOOD, 2011, 118 (21) : 1766 - 1766
  • [38] Response rates using international working group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    De Castro, CM
    Ellerton, J
    Knapp, KN
    Beach, CL
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
  • [39] Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
    Porwit, A.
    van de Loosdrecht, A. A.
    Bettelheim, P.
    Brodersen, L. Eidenschink
    Burbury, K.
    Cremers, E.
    Della Porta, M. G.
    Ireland, R.
    Johansson, U.
    Matarraz, S.
    Ogata, K.
    Orfao, A.
    Preijers, F.
    Psarra, K.
    Subira, D.
    Valent, P.
    van der Velden, V. H. J.
    Wells, D.
    Westers, T. M.
    Kern, W.
    Bene, M. C.
    LEUKEMIA, 2014, 28 (09) : 1793 - 1798
  • [40] Risk factors ana lyses for outcomes after unrelated cord blood transplantation for children with myelodysplastic syndromes. An analysis on behalf of EWOG-MDS and eurocord groups
    Moreno-Madureira, Adrienne B.
    Teira, Pierre
    Locatelli, Franco
    Piccardi, Alessandra
    Woolfrey, Ann
    Chan, Ka-Wah
    Socie, Gerard
    Vora, Ajay J.
    Bertrand, Yves
    Bonfim, Carmem
    Gamier, Federico
    Ionescu, Irina
    Gluckman, Eliane
    Niemeyer, Charlotte M.
    Rocha, Vanderson
    BLOOD, 2007, 110 (11) : 602A - 602A